Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-23
    E.g., 2018-09-23

Articles

173342 items
9:36 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Diagnostic companies Cancer Genetics, NovellusDx merging

Cancer diagnostic company Cancer Genetics Inc. (NASDAQ:CGIX) will merge with NovellusDx Ltd. (Jerusalem, Israel). NovellusDx shareholders will have a 49% equity stake in the company, which will retain Cancer Genetics’ name. NovellusDx’s assays distinguish passenger and...
9:35 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Prescient, Metabiomics partner for colon cancer diagnostics

Prescient Medicine Holdings LLC (Hummelstown, Pa.) and Metabiomics Corp. (Aurora, Colo.) formed a JV to develop and commercialize Metabiomics' microbiome diagnostics platform to detect precancerous colon polyps and diagnose other types of gastrointestinal diseases, including...
9:35 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Ono, Fate in off-the-shelf CAR T deal

Fate Therapeutics Inc. (NASDAQ:FATE) added $1.13 (10%) to $12.20 on Sept. 18 after partnering with Ono Pharmaceutical Co. Ltd. (Tokyo:4528) to develop and commercialize two off-the-shelf CAR T cell programs for cancer. The partners said...
9:34 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Servier declines rights to GeNeuro's GNbAC1

Servier (Neuilly-sur-Seine, France) declined to exercise an option to license rights outside the U.S. and Japan from GeNeuro S.A. (Euronext:GNRO) to develop and commercialize GNbAC1 to treat multiple sclerosis. The companies said Servier's decision was...
9:34 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Celenex takeout first of several expected Amicus gene therapy deals

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
9:34 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Molecular Templates extends deal with Takeda on engineered toxin bodies

Building on a previous discovery collaboration, Molecular Templates Inc. (NASDAQ:MTEM) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered Sept. 19 to develop CD38-targeting engineered toxin bodies (ETBs) to treat multiple myeloma. Molecular Templates will receive $30...
9:33 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Ex-Kite execs prep quick IPO for CAR T play Allogene

Cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, Cowen and Jefferies. Launched in April with...
9:33 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Arvinas amends IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) amended on Sept. 14 its proposed IPO on NASDAQ and now plans to sell 6.7 million shares at $14-$16. The offering is being underwritten by Goldman Sachs,...
9:33 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Biodesy raises $20M in series C, appoints new CEO

Biodesy Inc. (South San Francisco, Calif.) raised $20 million Sept. 10 in a series C round led by new investor Alexandria Venture Investments. Existing investors 5AM Ventures, Pfizer Ventures and Roche Venture Fund also participated...
9:32 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Principia jumps after $106.3M IPO

Principia Biopharma Inc. (NASDAQ:PRNB) leaped $15.65 (92%) to $32.65 on Sept. 14, its first day of trading, after raising $106.3 million late Sept. 13 through the sale of 6.3 million shares at $17 in an...

Pages